Post-ERCP pancreatitis occurred in 19 patients ( 7.5 % ) in the somatostatin group and 17 patients ( 6.7 % ) in the placebo group ( relative risk [ RR ] 1.12 , 95 % confidence interval [ 95 % CI ] 0.59-2 .1 ; P = 0.73 ) .